Previously doing business as Novelos Therapeutics, Inc., (OTC:NVLT.) based in MA, in February 2014 firm changed name to Cellectar Biosciences (NASDAQ:CLRB) with primary operations in Madison, WI. Firm Now operates in Florham Park, NJ., Cellectar is clinical biopharmaceutical company, structured aound discovery, development, and commercialization of drugs for the treatment of cancer. The firm's lead phospholipid drug conjugate (PDC) candidate is CLR 131, curently in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical stage to treat solid tumors. Cellectar has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; and IntoCell Inc.
